Journal list

Notice to the Extraordinary General Meeting of BioInvent International AB

LUND, SE /ACCESSWIRE/June 16, 2022/ BioInvent International (STO:BINV)

The shareholders of BioInvent International AB (publ), Reg. No 556537-7263, are invited to attend the Extraordinary General Meeting (the “AGE”) to be held on Tuesday July 12, 2022. The EGM will be held only by advance vote (postal vote) in accordance with the legislation temporary.

A. NOTICE OF MEETING

Shareholders wishing to attend the EGM must:

(i) be entered in the share register maintained by Euroclear Sweden AB (“Euroclear“), effective Monday, July 4, 2022; and

(ii) notify the company of their intention to participate in the EGM no later than Monday, July 11, 2022, by submitting their advance votes in accordance with the instructions under the heading “Advance votingbelow, so that the advance poll is received by BioInvent no later than that day.

Shareholders whose shares are registered must temporarily re-register their shares in their own name in the register of shareholders held by Euroclear in order to participate in the EGM (referred to as “registration of voting rights”). The registers of shareholders as of the record date of July 4, 2022 will include registrations of voting rights made no later than July 6, 2022. Accordingly, shareholders must, in accordance with the respective nominee routines, in good time before said date , ask their nominee to carry this record of voting rights.

Advance voting
Shareholders can only exercise their voting rights at the EGM by voting in advance, known as postal voting in accordance with article 20 of the law (2022:121) on temporary derogations to facilitate the execution of general meetings in societies and other associations.

A special form is used for advance voting. The form is available on the company’s website, www.bioinvent.se. The advance voting form constitutes notification of participation in the EGM.

The completed and signed voting form must reach BioInvent no later than Monday, July 11, 2022, kindly before 4:00 p.m. IT IS. The completed and signed form will be sent to BioInvent by e-mail at [email protected] or by regular mail to BioInvent International AB, Ideongatan 1, SE-223 70 Lund, Sweden, att: Stefan Ericsson. If the shareholder votes by proxy in advance, a proxy must be attached to the form. The proxy form is available on request and on the company’s website www.bioinvent.se. If the shareholder is a legal person, a copy of the registration certificate or, if this document does not exist, a similar authorization document must be attached. The shareholder may not give specific instructions or conditions to the postal vote. If so, the entire vote is invalid.

Further instructions and conditions are included in the Advance Voting Form.

B. RIGHT OF SHAREHOLDERS TO REQUEST INFORMATION

The board of directors and the managing director must, if a shareholder so requests, and if the board of directors considers that it can be done without material prejudice to the company, provide information on the circumstances likely to affect the appreciation of a point on the agenda. . Requests for such information should be made in writing to BioInvent International AB, Ideongatan 1, SE-223 70 Lund, Sweden, att: Stefan Ericsson or by e-mail to [email protected]no later than ten days before the EGM, i.e. no later than Saturday July 2, 2022. Information will be disclosed by being available from BioInvent International AB, Ideongatan 1, SE-223 70 Lund, Sweden, and on the company’s website, www.bioinvent.seno later than five days before the EGM, i.e. no later than Thursday July 7, 2022. The information will also be distributed to shareholders who request it, specifying their postal or electronic address.

C. AGENDA OF THE MEETING

Agenda proposal

1. Election of the Chairman of the meeting
2. Election of the person to approve the minutes
3. Preparation and approval of the voting list
4. Determination of compliance with the convening rules
5. Approval of the agenda
6. Fixing the number of members of the Board of Directors
7. Determination of attendance fees for members of the Board of Directors
8. Election of new members of the Board of Directors
(a) Nanna Lüneborg
(b) Natalie Berner

Suggestions for items on the agenda

Election of the chair of the meeting (item 1)

The Board of Directors proposes that the secretary of the Board and lawyer Madeleine Rydberger or, if she is unable to attend, the person designated by the Board of Directors, chair the meeting.

Election of the person to approve the minutes (item 2)

It is proposed that Erik Esveld, representing Van Herk Investments BV, or in case of impediment, the person appointed by the Board of Directors, be responsible for approving the minutes of the EGM with the Chairman. The mission to approve the minutes also includes verifying the voting list and that the advance votes received are correctly indicated in the minutes of the EGM.

Preparation and approval of the voting list (item 3)

The voting list proposed for approval is the voting list prepared by the company, based on the register of shareholders for the EGM prepared by Euroclear Sweden AB and the advance votes received, as verified and recommended by the person elected for approve the minutes.

Determination of compliance with the convening rules (point 4)

It is proposed that the EGM has been duly convened as approved by the Chairman of the meeting, based on the provisions of Swedish companies law and the articles of association concerning the convening of extraordinary general meetings.

Approval of the agenda (item 5)

It is proposed to approve the agenda included in the notice.

Elections and fees (points 6 to 8)

The Nominating Committee, consisting of Laura Feinleib (Redmile Group, LLC), Erik Esveld (Van Herk Investments BV), Vincent Ossipow (Omega Funds, LP) and Leonard Kruimer (Chairman of the Board), informed the company of what follows the proposals.

  • The board of directors has been increased by two directors and is now made up of eight members elected by the general meeting.
  • New election of Nanna Lüneborg and Natalie Berner as members of the board of directors for the period until the end of the next annual general meeting. Information on the proposed candidates for a new election is presented in a separate press release.
  • Annual fees per Board member (including fees for committee work), as decided by the Annual General Meeting of April 28, 2022, will continue to apply leading to some increase in total fees since the number of members of the Board is increased by two. Fees (including fees for committee work) shall be paid to new board members in proportion to the board member’s actual period of service over the entire period from the 2022 Annual General Meeting until the end of the next annual general meeting.

D. AVAILABLE DOCUMENTS ETC

Proxy forms and the early voting form are available on the company’s website, www.bioinvent.se. Other documents required to be kept available in accordance with Swedish company law will be available on the company’s website from Tuesday, June 21, 2022 at the latest, and will be distributed to shareholders who so request and provide their mailing address.

At the time of this notice, the total number of shares and votes in the company amounts to 58,471,096.

E. PROCESSING OF PERSONAL DATA

For more information on how your personal data is processed, see https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf.

_________________________

Monday in June 2022
Board of directors
BIOINVENT INTERNATIONAL AB (publisher)

About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotechnology company discovering and developing first-in-class novel immunomodulatory antibodies for the treatment of cancer, with currently three drug candidates in four ongoing clinical programs in Phase 1/ 2 trials for the treatment of hematological cancer and solid tumors, respectively; and a fifth program which has just entered clinical development. The company’s validated and proprietary FIRST™ technology platform simultaneously identifies targets and the antibodies that bind to them, generating many promising new drug candidates to feed into the company’s own clinical development pipeline or for in-licensing and additional partnerships.

The Company generates revenue from research collaborations and licensing agreements with several leading pharmaceutical companies, as well as from the production of antibodies for third parties in the Company’s fully integrated manufacturing unit. More information is available at www.bioinvent.com. Follow on Twitter: @BioInvent.

BioInvent International AB (publisher)
Co. Reg. Org No.: 556537-7263
Visiting address: Ideongatan 1
Postal address: 223 70 LUND
Telephone: +46 (0)46 286 85 50
www.bioinvent.com

Attachments

Notice to the Extraordinary General Meeting of BioInvent International AB

THE SOURCE: BioInvent International

See the source version on accesswire.com:
https://www.accesswire.com/705362/Notice-to-Extraordinary-General-Meeting-in-BioInvent-International-AB